

## Anat Naschitz

[anat@9vc.co](mailto:anat@9vc.co)

[LinkedIn](#)



Anat Naschitz is a lifescience investor and entrepreneur.

As Managing Partner at [9vc](#), she focuses on late-stage therapeutics, using tech, connectivity and experience to identify, derisk and upgrade investment opportunities.

Recently, Anat worked closely with [Leona Bio \(Nasdaq:LONA\)](#) and participated in a financing of up to [\\$236 million](#) alongside blue chip funds, supporting Leona's exclusive license to lasofoxifene, a Phase 3 metastatic breast cancer program.

Previously, Anat co-founded and was a partner at [OrbiMed](#) Israel as part of the \$20bn global firm, where she invested across the healthcare ecosystem including therapeutics, devices, digital health and computation.

One of her favorite investments is [89bio \(Nasdaq:ETNB\)](#), which she co-founded as a pharma spinout and supported as an active board member from inception, both pre and post IPO, through phase 3 in MASH and HSTG. In September 2025 [Roche acquired the company for up to \\$3.5bn](#).

Other investments include [Azura Ophthalmics](#), poised for a H2 2026 NDA submission of its first-in-class keratolytic therapy to restore meibomian gland function in dry eye patients, essentially treating the root cause of the disease; [ForSight Vision 6](#), developing a truly accommodating Intra Ocular Lens under a strategic collaboration; [TytoCare](#), a growth stage company transforming primary care with a highly accurate handheld device and software enabling a full exam at home; and [MDclone](#), reducing morbidity and mortality and enhancing drug development by sharing and analyzing synthetic data.

Prior to OrbiMed, Anat held senior positions at Apax and McKinsey London, where she was involved in creating what ultimately became [Sobi](#), a rare disease company (STE:SOBI, \$15bn mkt cap) through pharma spinout and M&A.

Anat serves on several boards of public and private companies. She is on the board and audit committee of Paris-based [Nanobiotix \(Nasdaq:NBTX\)](#), advancing several platforms of physics-based therapeutics. The company's 1<sup>st</sup> in class radio enhancers, including a phase 3 program for head & neck cancer, are being developed under a \$2.5bn partnership with Johnson & Johnson. Other boards include Lyon-based [Lys Therapeutics](#), soon to enter the clinic with antibodies designed to reverse blood-brain-barrier dysfunction; Chairperson, PeriNess, developing a drug for male fertility; Polaris QB, commercializing quantum annealing based tech to match the target binding site to the best molecule from a  $10^{30}$  chemical space; and ProFuse, converting its cultivated meat production capabilities into a drug discovery platform, using fully functional 3D skeletal muscles. She also advises [Remepy](#), entering phase 3 with a hybrid therapeutic, and [Camelot BioCapital](#), a US-based fund.

Anat's creativity extends beyond lifesciences. You can find some of her paintings and poetry at [www.9zebras.com](http://www.9zebras.com). She speaks multiple languages and is a very biased mother of 2 incredible young adults.